申请人:Gray Nathanael S.
公开号:US20090258910A1
公开(公告)日:2009-10-15
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2α, p38, TGFβ, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.
该发明提供了一类新型化合物,包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或调节酪氨酸激酶活性相关的疾病或紊乱,特别是涉及Abl、BCR-Abl、PDGF-R、lck、SAPK2α、p38、TGFβ、KDR、c-Kit、b-RAF、c-RAF、FLT1和FLT4激酶异常激活的疾病或紊乱的方法。